CN103820454B - The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene - Google Patents
The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene Download PDFInfo
- Publication number
- CN103820454B CN103820454B CN201410077474.6A CN201410077474A CN103820454B CN 103820454 B CN103820454 B CN 103820454B CN 201410077474 A CN201410077474 A CN 201410077474A CN 103820454 B CN103820454 B CN 103820454B
- Authority
- CN
- China
- Prior art keywords
- sgrna
- gene
- sequence
- plasmid
- seq idno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091027544 Subgenomic mRNA Proteins 0.000 title claims abstract description 112
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 title claims abstract description 20
- 238000003209 gene knockout Methods 0.000 claims abstract description 11
- 239000013612 plasmid Substances 0.000 claims description 71
- 108091034117 Oligonucleotide Proteins 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 39
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 238000000137 annealing Methods 0.000 claims description 28
- 230000008859 change Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000012163 sequencing technique Methods 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000012790 confirmation Methods 0.000 claims 1
- 210000002706 plastid Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000008685 targeting Effects 0.000 abstract description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000001890 transfection Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 108091033409 CRISPR Proteins 0.000 description 11
- 238000012797 qualification Methods 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 108091008042 inhibitory receptors Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 108010067770 Endopeptidase K Proteins 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 229930189065 blasticidin Natural products 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 229950010131 puromycin Drugs 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940125644 antibody drug Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to genetically engineered field, more particularly, relate to the method for CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene.The invention provides the method for CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene.The sgRNA of the selectively targeted people PD1 gene utilizing the present invention to prepare can accurate targeted human PD1 gene and realize gene knockout.This preparation method's step is simple, sgRNA targeting is good, CRISPR-Cas9 system to knock out efficiency high.
Description
Technical field
The invention belongs to genetically engineered field, more specifically to the method for CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene.
Background technology
Rule cluster interval short palindrome duplicated system (clusteredregularlyinterspacedshortpalindromicrepeat; CRISPR-associated, CRISPR-Cas9) be a kind of complex body with endonuclease activity, identify specific DNA sequence dna, carry out specific site cutting and cause double-strand DNA cleavage (Double-strandbreaks, DSB), under the condition not having template, there is non-homogeneous restructuring end and connect (Non-homologousendjoining, NHEJ), cause phase shift mutation (frameshiftmutation), cause gene knockout (Fig. 1).
This technology due to can fast, any gene of target gene group simply, efficiently, thus cause and pay close attention to widely, within 2012, to start picture explode bud out into popularity.Due to its easily operation, can the multiple gene of target simultaneously, can the advantages such as high-throughput preparation, cost be low, Cas9 has become a kind of technology with fastest developing speed (Pennisi, 2013).Just because of its superiority, this technology Nature recommend 2,013 ten to rank first in progress greatly (
http:// www.nature.com/news/365-days-nature-s-10-1.14367), be at the second place in the 2013 ten large progress that Science recommends (
http:// news.sciencemag.org/breakthrough-of-the-year-2013).
Cas9 target cutting DNA is by two kinds of tiny RNA---crRNA(CRISPRRNA) and tracrRNA (trans-activatingcrRNA) and target complement sequence identification principle realize.Two kinds of tiny RNA are fused into a RNA chain now, are called for short sgRNA(singleguideRNA).Therefore, can sgRNA accomplish that specificity, accurately target target gene are that can CRISPR-Cas9 the prerequisite of specific knockdown target gene, no matter misses the target or wrong target, all can affect the specific knockdown of CRISPR-Cas9 to target gene.Therefore, it is possible to the sgRNA designing, prepare accuracy and selectively targeted target gene becomes the gordian technique (Fig. 1) of CRISPR-Cas9 gene knockout.
Immunotherapy of tumors, especially to the blocking-up of immunologic test point, is the current the most successful field of target gene therapy.Immunologic test point refers to and maintains immune self tolerance, and regulates a series of inhibitive ability of immunity reactions of the immune response intensity under physiological condition and time length.Research shows, tumour cell and immunologic test point approach synergy, create the effect of Tumor suppression immunity, particularly the effect of the effector T cell of Tumor suppression antigen-specific.To the blocking-up of immunologic test point, refer to the monoclonal antibody utilizing T cell immunologic test Inhibitory receptor, the combination of specific inhibition Inhibitory receptor and its part, thus the effect of blocking immunity checking mechanism suppressor T cell activation, the antitumous effect of reinforcing effect T cell.
One of immunologic test target spot being used successfully to clinical immunotherapy of tumors is inhibitive ability of immunity acceptor, PD1 gene.The major function of PD1 is the effector T cell activity of restriction peripheral tissues.The PD1 part of tumor cells expression and the PD1 of T cell combine, and suppressor T cell activates associated kinase, thus retarding effect T cell is active.Utilize PD1 monoclonal antibody (MDX-1106, MK3475, CT-011, AMP-224 etc.), suppress PD1 part and PD1 to combine, thus reach the effect for the treatment of tumour.
But, utilize the treatment of PD1 antibody only better in malignant melanoma curative effect, have part curative effect to kidney and lung cancer.Because the treatment utilizing antibody to carry out target gene is also subject to the restriction of some factors: the effect of (1) antibody is the effect of temporary interruption; (2) Inhibitory receptor has multiple, and how to utilize Multiple Antibodies to block multiple Inhibitory receptor does not also have countermeasure simultaneously; (3) be not easy to develop effective antibody; (4) only for extracellular target spot; (5) antibody drug is expensive, etc.
CRISPR-Cas9 is quick, easy, efficient, selectively targeted knocks out gene, knocks out PD1 gene by target, provides a kind of key tactics for realizing immunotherapy of tumors.But can the sgRNA that design, prepare accuracy and selectively targeted PD1 gene become the gordian technique of CRISPR-Cas9 specific knockdown PD1 gene.Object of the present invention will solve this key technical problem exactly, provides corresponding technical scheme, reaches the object of specific knockdown PD1 gene.
Reference:
MaliP,EsveltKM,ChurchGM.Cas9asaversatiletoolforengineeringbiology.Nat.Methods.2013;10(10):957-963.
PennisiE.TheCRISPRcraze.Science,2013;341(6148):833-6.doi:10.1126/science.341.6148.833.
PardollDM.Theblockadeofimmunecheckpointsincancerimmunotherapy.NatureRev.Cancer,2012;12:252-264.
MellmanI,CoukosG,DranoffG.Cancerimmunotherapycomesofage.Nature,2011;480:480-489.
Summary of the invention
Immunodetection blocking treatment tumour Problems existing is carried out: the effect of (1) antibody is the effect of temporary interruption for the existing PD1 of utilization antibody; (2) Inhibitory receptor has multiple, and how utilizing Multiple Antibodies to block multiple Inhibitory receptor does not also have countermeasure; (3) be not easy to develop effective antibody; (4) only for extracellular target spot; (5) develop that antibody drug is time-consuming, effort, expensive, make antibody drug expensive.The present invention designs, has synthesized the sgRNA of one group of selectively targeted PD1 gene in CRISPR-Cas9 specific knockdown people PD1 gene, and respectively this sgRNA and linear pGL3-U6-sgRNA plasmid are connected into carrier, a pair forward can be realized knocking out of PD1 gene with direction sgRNA oligonucleotide carrier Successful transfection cell together with pST1374-NLS-flag-Cas9-ZF plasmid.This application provides and a kind ofly utilize that Cas9/sgRNA is quick, easy, efficient, the strategy of specific knockdown PD1.Efficiently solve and utilize Antybody therapy Problems existing: (1) directly knocks out PD1 gene, permanent effect can be realized; (2) both can knock out for multiple encoding sequences of PD1 simultaneously, also can knock out for multiple target gene simultaneously; (3) efficient sgRNA is provided; (4) both can for outside born of the same parents, also can for target spot in born of the same parents; (5) sgRNA only needs synthetic polyribonucleotides segment in a small amount, just can produce in enormous quantities.
In order to solve the problems of the technologies described above, the technical scheme of the application is as follows:
One, the design of sgRNA oligonucleotide and selection
1. the design of the sgRNA of target PD1 gene:
Because do not use in-vitro transcription, the mode just building general carrier makes.So if no special instructions, the sgRNA sequence in literary composition refers to sgRNA corresponding DNA sequence.
(1) on PD1 gene, select the sequence of 5 '-GGN (19) GG, if do not have the sequence of 5 '-GGN (19) GG, 5 '-GN (20) GG or 5 '-N (21) GG is also passable.
(2) target site of sgRNA on PD1 gene is positioned at the exon of gene.
(3) target site of sgRNA on PD1 gene is positioned on the common exon of different various shear-forms.
(4) in UCSC database, use BLAST with in BLAT or ncbi database, determine that whether the target sequence of sgRNA is unique.
2. the selection of the sgRNA of target PD1 gene:
(1) can not from the initial son of ATG too close to, prevent from transcribing another ATG of downstream after the meeting and start and occur that one by the gene forms of brachymemma, gene complete deactivation can not be ensured;
(2) target site of sgRNA on PD1 gene is positioned at the first half section of whole gene, especially should in the functional domain of gene;
(3) site selecting (10 ~ 30bp) separated by a distance paired.Be conducive to like this forming specific fragment deletion, be also conducive to reduction and miss the target effect;
Two, the double strand oligonucleotide of sgRNA is built
According to the sgRNA selected, 5 ' add that CCGG obtains forward oligonucleotide (Forwardoligo) (as infructescence itself has had 1 or 2 G at 5 ' end, the so omission 1 of correspondence or 2 G) at it; According to the sgRNA selected, obtain the complementary strand of its corresponding DNA, and 5 ' add that AAAC obtains reverse oligonucleotide (Reverseoligo) at it.Synthesize above-mentioned forward oligonucleotide and reverse oligonucleotide respectively, by the paired sex change of forwardoligo and reverseoligo of the sgRNA oligonucleotide of synthesis, annealing, after annealing, form the double-strand that can be connected into U6 carrier for expression of eukaryon, as follows:
Forwardoligo:5′-CCGGNNNNNNNNNNNNNNNNNN
||||||||||||||||||
Reverseoligo:NNNNNNNNNNNNNNNNNNCAAA-5′
Three, the structure of sgRNA oligonucleotide plasmid
1. linearizing pGL3-U6-sgRNA plasmid (structure as shown in Figure 4).
2. the sgRNA double strand oligonucleotide of annealing is connected with linearizing pGL3-U6-sgRNA plasmid and obtains pGL3-U6-hPD1sg plasmid.
3. transform and be coated with Amp+ flat board (50 μ g/ml).
4. with the method qualification positive colony that the universal primer U6 of IDNO.9 checks order.
5.37 DEG C of shaking tables shake bacterium and spend the night and use AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting pGL3-U6-hPD1sg plasmid.
Four, transfectional cell obtains PD1 Knockout cells
1, according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), the pST1374-NLS-flag-Cas9-ZF plasmid (structure as shown in Figure 5) being SEQIDNO.11 by the pGL3-U6-hPD1sg plasmid (can be a kind or multiple) respectively with corresponding sgRNA oligonucleotide and sequence mixes, cotransfection cell.
2, detection is cut with T7EN1 enzyme and TA cloning and sequencing confirms that PD1 gene is knocked.
Further, utilize the sgRNA of a pair adjacent (the target initiation site on PD1 gene is at a distance of 5bp-8bp) to significantly improve simultaneously and knock out efficiency.After the sgRNA oligonucleotide design of target PD1, selection and synthesis, the sgRNA oligonucleotide of target PD1 is connected the carrier pGL3-U6-hPD1sg of the sgRNA oligonucleotide obtained containing target PD1 with linearizing pGL3-U6-sgRNA plasmid, obtain in PD1 Knockout cells process at transfectional cell, operate as follows:
1, according to Lipofectamine
tM2000TransfectionReagent(Invitrogen; operational manual 11668-019); by two respectively containing the sgRNA oligonucleotide of 1 target PD1 these two carriers of carrier pGL3-U6-hPD1sg(respectively with complementary initiation site on PD1 gene of the sgRNA oligonucleotide of target PD1 at a distance of 5bp-8bp) being SEQIDNO.11 with sequence, pST1374-NLS-flag-Cas9-ZF plasmid mixes, cotransfection cell.
2, detection is cut with T7EN1 enzyme and TA cloning and sequencing confirms that PD1 gene is knocked.
Present invention also offers the sgRNA of selectively targeted PD1 gene, its sequence is as shown in SEQIDNO.24-203.
Carry out immunodetection blocking treatment tumour technology compared to the existing PD1 of utilization antibody, the invention has the advantages that:
(1) effect of antibody is the effect of temporary closure, and the present invention directly knocks out PD1 gene, can realize permanent effect;
(2) Inhibitory receptor has multiple, and how utilizing Multiple Antibodies to close multiple Inhibitory receptor does not also have countermeasure, and the present invention both can knock out for multiple encoding sequences of PD1, also can knock out for multiple target gene;
(3) effective PD1 antibody research and development are very difficult, the invention provides one group of efficient sgRNA for people PD1 gene;
(4) antibody effect can only for extracellular target spot, and the present invention both can for outside born of the same parents, also can for target spot in born of the same parents;
(5) developing antibody drug is time-consuming, effort, an expensive process, makes antibody drug expensive, utilizes sgRNA only to need synthetic polyribonucleotides segment in a small amount, just can produce in enormous quantities.
Accompanying drawing explanation
Fig. 1 Cas9 realizes fixed point cutting and causes DNA double chain-breaking process schematic diagram
CRISPR/Cas9 system oriented identification and shearing thus cause gene knockout to be realized by sgRNA and Cas9.SgRNA determines the targeting of Cas9.
Fig. 2 T7EN1 enzyme cuts the gene people PD1 specificity cutting of qualification sgRNA/Cas9 mediation
With the HEK293T cellular genome extracted for template, use sequence as hPD1testFor and hPD1testRev of SEQIDNO.12 and SEQIDNO.13 for primer carries out pcr amplification, PCR primer is 390bp, purified pcr product.Above-mentioned PCR primer is got 200ng annealing, use T7EN1 enzyme to cut qualification, electrophoresis.As shown in Figure 2, all there is cutting band, and had very high efficiency in the sample added for the sgRNA of people PD1.
The gene locus specific human PD1 that Fig. 3 sgRNA/Cas9 mediates cuts result order-checking
With the cellular genome extracted for template, use sequence as hPD1testFor and hPD1testRev of SEQIDNO.12 and SEQIDNO.13 for primer carries out pcr amplification.Purified pcr product, is connected into TA and clones and send order-checking.Underlined sequences is PAM sequence; (-) expression knocks out.
The structure of Fig. 4 carrier pGL3-U6-sgRNA
The structure of Fig. 5 carrier pST1374-NLS-flag-cas9-ZF
Embodiment
Below in conjunction with accompanying drawing and specific embodiment, technical scheme of the present invention is described further.
For the design of the sgRNA of selectively targeted PD1 gene and synthesis in embodiment 1CRISPR-Cas9 specific knockdown people PD1 gene
1. the design of the sgRNA of targeted human PD1 gene:
(1) on PD1 gene, select the sequence of 5 '-GGN (19) GG, if do not have the sequence of 5 '-GGN (19) GG, 5 '-GN (20) GG or 5 '-N (21) GG is also passable.
(2) target site of sgRNA on PD1 gene is positioned at the exon of gene, so more easily causes the disappearance of fragment or moves frame sudden change, thus reach the object of gene complete deactivation.
(3) target site of sgRNA on PD1 gene is positioned on the common exon of different various shear-forms.
(4) in UCSC database, use BLAST with in BLAT or ncbi database, determine that whether the target sequence of sgRNA is unique, reduce potential site of missing the target.
According to above method, we devise altogether the sgRNA of 180 targeted human PD1 genes, and sequence is respectively as shown in sequence table SEQ IDNO.24-203.
2. the selection of the sgRNA of targeted human PD1 gene:
(1) target sequence of the sgRNA of target PD1 gene on PD1 gene can not from the initial son of ATG too close to, prevent from transcribing another ATG of downstream after the meeting and start and occur that one by the gene forms of brachymemma, gene complete deactivation can not be ensured.
(2) target site of sgRNA on PD1 gene is positioned at the first half section of whole gene, especially should in the functional domain of gene.
(3) site selecting (10 ~ 30bp) separated by a distance paired on PD1 gene.Be conducive to like this forming specific fragment deletion, be also conducive to reduction and miss the target effect.
According to above method, in the sgRNA(sequence comprising PAM sequence of 180 targeted human PD1 genes respectively as shown in sequence table SEQ IDNO.24-203) in the sequence that meets have 12 (respectively as shown in sequence table SEQ IDNO.40,51,52,57,63,78,82,96,101,126,128 or 136), because sequence is more, there is no need to do experimental verification one by one, we therefrom have selected 4 (respectively as sequence table SEQ IDNO.52,57, shown in 78 or 82) carry out subsequent experimental.
3. the synthesis of the sgRNA oligonucleotide of targeted human PD1 gene and structure
According to 4 that select (respectively as shown in sequence table SEQ IDNO.52,57,78 or 82), 5 ' add that CCGG obtains forward oligonucleotide (Forwardoligo) (as infructescence itself has had 1 or 2 G at 5 ' end, so corresponding omission 1 or 2 G) at it; According to the sgRNA selected, obtain its complementary strand, and 5 ' add that AAAC obtains reverse oligonucleotide (Reverseoligo) at it.(synthetic method is see document: Significantimprovementofqualityforlongoligonucleotidesby usingcontrolledporeglasswithlargepores.NucleosidesNucleo tidesNucleicAcids.2005 in synthesis respectively; 24 (5-7): 1037-41.) above-mentioned forward oligonucleotide and reverse oligonucleotide, by the paired sex change of forwardoligo and reverseoligo of the sgRNA oligonucleotide of synthesis, annealing, form the double-strand sgRNA oligonucleotide that can be connected into U6 carrier for expression of eukaryon after annealing, pattern is as follows:
Forwardoligo:5′-CCGGNNNNNNNNNNNNNNNNNN
||||||||||||||||||
Reverseoligo:NNNNNNNNNNNNNNNNNNCAAA-5′
Sex change, annealing system are:
2.5μlforwardOligo(100μM)
2.5μlreverseOligo(100μM)
1μlNEBbuffer2
4 μ l aqua sterilisas
Run according to following touchdown program in PCR instrument: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
The 1st sgRNA(selected is as shown in sequence table SEQ IDNO.52), itself forwardoligo and reverseoligo(Forwardoligo and Reverseoligo sequence are respectively as Suo Shi sequence table SEQ IDNO.1 and 2) in pairs sex change, after annealing acquisition can be connected into the double-strand sgRNA oligonucleotide of U6 carrier for expression of eukaryon.
The 2nd sgRNA(selected is as shown in sequence table SEQ IDNO.82), itself forwardoligo and reverseoligo(Forwardoligo and Reverseoligo sequence are respectively as Suo Shi sequence table SEQ IDNO.3 and 4) in pairs sex change, after annealing acquisition can be connected into the double-strand sgRNA oligonucleotide of U6 carrier for expression of eukaryon.
The 3rd sgRNA(selected is as shown in sequence table SEQ IDNO.57), itself forwardoligo and reverseoligo(Forwardoligo and Reverseoligo sequence are respectively as Suo Shi sequence table SEQ IDNO.5 and 6) in pairs sex change, after annealing acquisition can be connected into the double-strand sgRNA oligonucleotide of U6 carrier for expression of eukaryon.
The 4th sgRNA(selected is as shown in sequence table SEQ IDNO.78), itself forwardoligo and reverseoligo(Forwardoligo and Reverseoligo sequence are respectively as Suo Shi sequence table SEQ IDNO.7 and 8) in pairs sex change, after annealing acquisition can be connected into the double-strand sgRNA oligonucleotide of U6 carrier for expression of eukaryon.
Embodiment 2 utilizes CRISPR-Cas9 specific knockdown people PD1 gene (sgRNA for target PD1 gene is as shown in sequence table 52)
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.1 is with 2 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg1 plasmid.
Linked system is as follows:
3 μ l, 50 μMs of annealed product (double-strand sgRNA oligonucleotide, its forwardoligo is as shown in sequence table SEQ IDNO.1, and its reverseoligo is as shown in sequence table SEQ IDNO.2)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
4, connection product conversion DH5 α competent cell (TransGen, CD201) above-mentioned steps obtained also is coated with Amp+ flat board (50 μ g/ml), and picked clones.
5, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
6,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg1 plasmid (as shown in sequence table SEQ IDNO.14).
7, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), by 0.5 μ gpGL3-U6-hPD1sg1(as shown in sequence table SEQ IDNO.14) mix with the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.11) of 1.5 μ g, in cotransfection to every porocyte, change liquid after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, collected cell after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transforms DH5 α competent cell (TransGen, CD201).
(2) picking mono-clonal is with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, and finds according to sequencing result (as shown in sequence table SEQ IDNO.18): target gene PD1 has lacked one section of sequence of sgRNA target, gene knockout success.
Embodiment 3 utilizes CRISPR-Cas9 specific knockdown people PD1 gene (for the sgRNA of target PD1 gene as shown in sequence table SEQ IDNO.82)
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.3 is with 4 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg1 plasmid.
Linked system is as follows:
3 μ l50 μMs of annealed product double-strand sgRNA oligonucleotides, its forwardoligo is as shown in sequence table SEQ IDNO.3, and its reverseoligo is as shown in sequence table SEQ IDNO.4)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
4, connection product conversion DH5 α competent cell (TransGen, CD201) above-mentioned steps obtained also is coated with Amp+ flat board (50 μ g/ml), and picked clones.
5, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
6,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg2 plasmid (as shown in sequence table SEQ IDNO.15).
7, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.11) of 0.5 μ gpGL3-U6-hPD1sg2 plasmid (as shown in sequence table SEQ IDNO.15) with 1.5 μ g is mixed, in cotransfection to every porocyte, change liquid after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, collected cell after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transforms DH5 α competent cell (TransGen, CD201).
(2) picking mono-clonal is with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, and finds according to sequencing result (as shown in sequence table SEQ IDNO.19): target gene PD1 has lacked one section of sequence of sgRNA target, gene knockout success.
Embodiment 4 utilizes CRISPR-Cas9 specific knockdown people PD1 gene (for the sgRNA of target PD1 gene as shown in sequence table SEQ IDNO.57)
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.5 is with 6 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg1 plasmid.
Linked system is as follows:
3 μ l50 μM annealed product (double-strand sgRNA oligonucleotide, its forwardoligo is as shown in sequence table SEQ IDNO.5, and its reverseoligo is as shown in sequence table SEQ IDNO.6)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
4, connection product conversion DH5 α competent cell (TransGen, CD201) above-mentioned steps obtained also is coated with Amp+ flat board (50 μ g/ml), and picked clones.
5, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
6,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg3(as shown in sequence table SEQ IDNO.16).
7, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.10) of 0.5 μ gpGL3-U6-hPD1sg3 plasmid (as shown in sequence table SEQ IDNO.16) with 1.5 μ g is mixed, in cotransfection to every porocyte, change liquid after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, collected cell after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transforms DH5 α competent cell (TransGen, CD201).
(2) picking mono-clonal is with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, and finds according to sequencing result (as shown in sequence table SEQ IDNO.20): target gene PD1 lacks the sequence of sgRNA target, gene knockout success.
Embodiment 5 utilizes CRISPR-Cas9 specific knockdown people PD1 gene (for the sgRNA of target PD1 gene as shown in sequence table SEQ IDNO.78)
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.7 is with 8 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg4 plasmid.
Linked system is as follows:
3 μ l50 μM annealed product (double-strand sgRNA oligonucleotide, its forwardoligo is as shown in sequence table SEQ IDNO.7, and its reverseoligo is as shown in sequence table SEQ IDNO.8)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
3, connection product conversion DH5 α competent cell (TransGen, CD201) above-mentioned steps obtained also is coated with Amp+ flat board (50 μ g/ml), and picked clones.
4, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
5,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg4(as shown in sequence table SEQ IDNO.17).
6, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), by 0.5 μ gpGL3-U6-hPD1sg4(as shown in sequence table SEQ IDNO.17) mix with the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.11) of 1.5 μ g, in cotransfection to every porocyte, change liquid after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, collected cell after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transforms DH5 α competent cell (TransGen, CD201).
(2) picking mono-clonal is with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, and finds according to sequencing result (as shown in sequence table SEQ IDNO.21): target gene PD1 lacks the sequence of sgRNA target, gene knockout success.
Embodiment 6 utilizes CRISPR-Cas9 specific knockdown people PD1 gene
SgRNA for target PD1 gene is two sgRNA targets altogether, and its sequence is as shown in sequence table SEQ IDNO.52 and 82, and the target initiation site of these two sgRNA on PD1 gene, at a distance of 5bp, can significantly improve and knock out efficiency.
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.1 is with 2 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg1 plasmid.
By the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.3 is with 4 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg2 plasmid.
Linked system is as follows:
3 μ l50 μM annealed product (double-strand sgRNA oligonucleotides, its forwardoligo is as shown in sequence table SEQ IDNO.1, its reverseoligo is as shown in sequence table SEQ IDNO.2) or (double-strand sgRNA oligonucleotide, its forwardoligo is as shown in sequence table SEQ IDNO.3, and its reverseoligo is as shown in sequence table SEQ IDNO.4)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
4, the connection product that above-mentioned steps obtains is transformed DH5 α competent cell (TransGen, CD201) respectively and is coated with Amp+ flat board (50 μ g/ml), and picked clones.
5, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
6,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg1(as shown in sequence table SEQ IDNO.14) and pGL3-U6-hPD1sg2(as shown in sequence table SEQ IDNO.15).
7, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), by 0.5 μ gpGL3-U6-hPD1sg1(as shown in sequence table SEQ IDNO.14) and 0.5 μ gpGL3-U6-hPD1sg2(as shown in sequence table SEQ IDNO.15) mix with the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.11) of 1.5 μ g, in cotransfection to every porocyte, liquid is changed after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, collected cell after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
As shown in Figure 2, can be found by agarose gel electrophoresis: occur broken ends connect the genome repaired can because with protogene group Incomplete matching, and to be cut by T7EN1.Demonstrate less band.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transforms DH5 α competent cell (TransGen, CD201).
(2) picking mono-clonal with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, find according to sequencing result (as shown in sequence table SEQ IDNO.22): target gene PD1 has lacked one section, the centre of two sgRNA target sequences, gene knockout success (as shown in Figure 3).
Embodiment 7 utilizes CRISPR-Cas9 specific knockdown people PD1 gene
SgRNA for target PD1 gene is two sgRNA targets altogether, and its sequence is as shown in sequence table SEQ IDNO.57 and 78, and the target initiation site of these two sgRNA on PD1 gene, at a distance of 8bp, can significantly improve and knock out efficiency.
1, the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10.
Enzyme cuts system and condition is as follows:
2μgpGL3-U6-sgRNA（400ng/μl）；
1μlCutSmartBuffer；
1μlBsaI(NEB，R0535L)；
Moisturizing to 50 μ l, hatches 3 ~ 4 hours for 37 DEG C, vibrates at set intervals and centrifugal in case droplet evaporation covers to pipe.
Enzyme cuts into rear AxyPrepPCRCleanupKit(AP-PCR-250) purifying is recycled in 20 ~ 40 μ l aqua sterilisas.
2, by the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.5 is with 6 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg3 plasmid.
By the double-strand sgRNA oligonucleotide (itself Forwardoligo with Reverseoligo sequence is respectively if sequence table SEQ IDNO.7 is with 8 Suo Shi) that can be connected into U6 carrier for expression of eukaryon of acquisition after sex change, annealing, being connected with linearizing pGL3-U6-sgRNA plasmid obtains pGL3-U6-hPD1sg4 plasmid.
Linked system is as follows:
3 μ l50 μM annealed product (sgRNA oligonucleotides, its forwardoligo is as shown in sequence table SEQ IDNO.5, its reverseoligo is as shown in sequence table SEQ IDNO.6) or (sgRNA oligonucleotide, its forwardoligo is as shown in sequence table SEQ IDNO.7, and its reverseoligo is as shown in sequence table SEQ IDNO.8)
The linearizing pGL3-U6-sgRNA plasmid of 1 μ l (25ng/ μ l)
1μlT4ligationBuffer
0.5μlT4ligase(NEB，M0202S)
4.5 μ l aqua sterilisas
Hatch 1 hour for 16 DEG C.
4, connection product difference transformed competence colibacillus cell DH5 α (TransGen, CD201) above-mentioned steps obtained also is coated with Amp+ flat board (50 μ g/ml), and picked clones.
5, with the universal primer U6 such as shown in sequence table SEQ IDNO.9, positive colony is obtained with the method qualification of routine order-checking.
6,37 DEG C of shaking tables shake bacterium incubated overnight positive colony, and with AxyPrepPlasmidMiniprepKit(AP-MN-P-250) extracting plasmid, obtain pGL3-U6-hPD1sg3 plasmid (as shown in sequence table SEQ IDNO.16) and pGL3-U6-hPD1sg4 plasmid (as shown in sequence table SEQ IDNO.17).
7, cell cultures and transfection
(1) HEK293T cell inoculation culture is in the high sugared nutrient solution of DMEM (HyClone, SH30022.01B), wherein containing 10%FBS, penicillin(100U/ml) and streptomycin(100 μ g/ml).
(2) divide in 12 orifice plates before transfection, when 70% ~ 80% density, carry out transfection.
(3) according to Lipofectamine
tM2000TransfectionReagent(Invitrogen, operational manual 11668-019), 0.5 μ gpGL3-U6-hPD1sg3 plasmid (as shown in sequence table SEQ IDNO.16) and 0.5 μ gpGL3-U6-hPD1sg4 plasmid (as shown in sequence table SEQ IDNO.17) are mixed with the pST1374-NLS-flag-Cas9-ZF plasmid (as shown in sequence table SEQ IDNO.11) of 1.5 μ g, in cotransfection to every porocyte, liquid is changed after 6 ~ 8 hours, and add Blasticidin(Sigma, 15205) and Puromycin(Merck, 540411) medicine sieve, cell is collected after 48 hours.
The preparation method of plasmid pST1374-NLS-flag-Cas9-ZF is see document: Shenetal.2013, Generationofgene-modifiedmiceviaCas9/RNA-mediatedgenetar geting.CellResearch23,720-723.(doi:10.1038/cr.2013.46)
8, T7EN1 enzyme cuts detection
(1), after the cell collected being digested with 100 μ g/ml Proteinase K cracking in lysate (10 μMs of Tris-HCl, 0.4MNaCl, 2 μMs of EDTA, 1%SDS), be dissolved into after phenol-chloroform extracting in 50 μ l deionized waters.
(2) primer hPD1testFor and hPD1testRev of sequence as SEQIDNO.12 and SEQIDNO.13 is used to carry out pcr amplification, purify with AxyPrepPCRcleanup and obtain PCR recovery product, get that 200ng is unified to be diluted to 20 μ l and to carry out sex change, annealing, program as: 95 DEG C, 5min; 95 – 85 DEG C at-2 DEG C/s; 85 – 25 DEG C at-0.1 DEG C/s; Holdat4 DEG C.
(3) in 20 μ l systems, add T7EN10.3 μ l, after 37 DEG C of enzymes cut 30 minutes, add 2 μ l10XLoadingBuffer, the agarose gel electrophoresis with 2.5% detects.
As shown in Figure 2, can be found by agarose gel electrophoresis: occur broken ends connect the genome repaired can because with protogene group Incomplete matching, and to be cut by T7EN1.Demonstrate less band.
9, TA cloning and sequencing
(1) T7EN1 enzyme is cut PCR that detecting step (2) obtains to reclaim product rTaq and carry out adding A reaction.Adding A reaction system is:
700 ~ 800ngPCR reclaims product
5μl10XBuffer(Mg
2+free)
3μlMg
2+
4μldNTP
0.5μlrTaq(TAKARA,R001AM)
Moisturizing to 50 μ l system.
37 DEG C of incubations are after 30 minutes, get 1 μ l product and pMD19-Tvector (TAKARA, 3271) connects and transformed competence colibacillus cell DH5 α (TransGen, CD201).
(2) picking mono-clonal with sequence as the universal primer U6 of sequence table SEQ IDNO.9 checks order, find according to sequencing result (as shown in sequence table SEQ IDNO.23): target gene PD1 has lacked one section, the centre of two sgRNA target sequences, gene knockout success (as shown in Figure 3).
Claims (1)
- The method of 1.CRISPR-Cas9 specific knockdown people PD1 gene, the method is used for non-diagnostic or therapeutic purpose, it is characterized by and comprises the steps:(1) sgRNA is provided, the target sequence of described sgRNA on PD1 gene meets the series arrangement rule of 5 '-N (21) GG, the target sequence of described sgRNA on PD1 gene is positioned at the exon of gene, the target sequence of described sgRNA on PD1 gene is positioned on the common exon of different various shear-forms, the target sequence of described sgRNA on PD1 gene is unique, and the target site sequence of described sgRNA on PD1 is as sequence table SEQ IDNO.52, 57, shown in 78 or 82 any sequences, add that CCGG synthesis obtains forward oligonucleotide and Forwardoligo at 5 ' of the target site sequence of described sgRNA on PD1, obtain the complementary strand of the target site sequence of sgRNA on PD1, and add that AAAC synthesis obtains reverse oligonucleotide and Reverseoligo at 5 ' of complementary strand, by 1 of synthesis to the paired sex change of forwardoligo and reverseoligo of the sgRNA oligonucleotide of complementation, annealing, after annealing, form the double-strand sgRNA oligonucleotide that can be connected into U6 carrier for expression of eukaryon,(2) the pGL3-U6-sgRNA plasmid of linearizing sequence as shown in sequence table SEQ IDNO.10; The double-strand sgRNA oligonucleotide of annealing is connected with linearizing pGL3-U6-sgRNA plasmid and obtains pGL3-U6-hPD1sg plasmid; PGL3-U6-hPD1sg Plastid transformation competence bacterium is also coated with Amp+ flat board, and picking mono-clonal also identifies positive colony with the universal primer U6 of sequence as shown in sequence table SEQ IDNO.9 by order-checking; 37 DEG C of shaking tables shake positive colony bacterium and spend the night and use article No. to be the AxyPrepPlasmidMiniprepKit extracting pGL3-U6-hPD1sg plasmid of AP-MN-P-250;(3) Lipofectamine is used tM2000TransfectionReagent loading pGL3-U6-hPD1sg plasmid and sequence are the pST1374-NLS-flag-Cas9-ZF plasmid of SEQIDNO.11, cotransfection cell;(4) cut with T7EN1 enzyme and to detect and TA cloning and sequencing confirmation PD1 gene has been knocked and has obtained the cell of gene knockout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410077474.6A CN103820454B (en) | 2014-03-04 | 2014-03-04 | The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410077474.6A CN103820454B (en) | 2014-03-04 | 2014-03-04 | The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103820454A CN103820454A (en) | 2014-05-28 |
| CN103820454B true CN103820454B (en) | 2016-03-30 |
Family
ID=50755743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410077474.6A Active CN103820454B (en) | 2014-03-04 | 2014-03-04 | The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103820454B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| JP2016536021A (en) | 2013-11-07 | 2016-11-24 | エディタス・メディシン，インコーポレイテッド | CRISPR-related methods and compositions with governing gRNA |
| JP6772062B2 (en) * | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | Cancer immunotherapy |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| CN104178512B (en) * | 2014-05-30 | 2017-07-21 | 广州辉园苑医药科技有限公司 | A kind of androgen receptor gene knocks out kit |
| CN104109687A (en) * | 2014-07-14 | 2014-10-22 | 四川大学 | Construction and application of Zymomonas mobilis CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-association proteins)9 system |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| CN104531857A (en) * | 2014-12-19 | 2015-04-22 | 安特诺生物医药（厦门）有限公司 | PD-1 gene armored RNA standard substance and applications thereof |
| CN104673816A (en) * | 2015-03-05 | 2015-06-03 | 广东医学院 | PCr-NHEJ (non-homologous end joining) carrier as well as construction method of pCr-NHEJ carrier and application of pCr-NHEJ carrier in site-specific knockout of bacterial genes |
| CN104805118A (en) * | 2015-04-22 | 2015-07-29 | 扬州大学 | A method for targeted knockout of specific genes in Suqin yellow chicken embryonic stem cells |
| CN105886498A (en) * | 2015-05-13 | 2016-08-24 | 沈志荣 | Method for specifically knocking out human PCSK9 gene by virtue of CRISPR-Cas9 and sgRNA for specifically targeting PCSK9 gene |
| CN105518137B (en) * | 2015-06-11 | 2021-04-30 | 深圳市第二人民医院 | Method for specifically knocking out pig SALL1 gene by CRISPR-Cas9 and sgRNA for specifically targeting SALL1 gene |
| WO2017031760A1 (en) * | 2015-08-27 | 2017-03-02 | 杨光华 | Interference fragment and applications thereof |
| WO2017031761A1 (en) * | 2015-08-27 | 2017-03-02 | 杨光华 | Interference fragment and applications thereof |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| CN105462968B (en) * | 2015-12-07 | 2018-10-16 | 北京信生元生物医学科技有限公司 | It is a kind of targeting apoC III CRISPR-Cas9 systems and its application |
| CN105561342A (en) * | 2016-01-27 | 2016-05-11 | 苏州佰通生物科技有限公司 | Gene medicine for treating hepatitis B and preparation method thereof |
| CN105671083B (en) * | 2016-02-03 | 2017-09-29 | 安徽柯顿生物科技有限公司 | The gene recombined virus plasmids of PD 1 and structure, the Puro of recombinant retrovirus Lenti PD 1 and packaging and application |
| CN105821040B (en) * | 2016-03-09 | 2018-12-14 | 李旭 | Combined immunization gene inhibits sgRNA, gene knockout carrier and its application of high-risk HPV expression |
| CN105821039B (en) * | 2016-03-09 | 2020-02-07 | 李旭 | Specific sgRNA combined with immune gene to inhibit HBV replication, expression vector and application of specific sgRNA |
| CN106399306B (en) * | 2016-04-12 | 2019-11-05 | 西安交通大学第一附属医院 | Target sgRNA, genophore and its application that people lncRNA-UCA1 inhibits bladder cancer |
| CN106434752A (en) * | 2016-06-14 | 2017-02-22 | 南通大学附属医院 | Process of knocking out Wnt3a gene and verification method thereof |
| EP3476865B1 (en) | 2016-06-28 | 2023-09-13 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Method for constructing pd-1 gene-modified humanized animal model and use thereof |
| CN107586777A (en) * | 2016-07-08 | 2018-01-16 | 上海吉倍生物技术有限公司 | People's PDCD1 genes sgRNA purposes and its related drugs |
| CN106191062B (en) * | 2016-07-18 | 2019-06-14 | 广东华南疫苗股份有限公司 | A kind of TCR-/PD-1- double negative T cell and its construction method |
| SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN106480097A (en) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | Knocking out that people PD 1 is gene constructed using CRISPR/Cas9 technology can the method for targeting MSLN novel C AR T cell and its application |
| CN106399375A (en) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | Method for constructing CD19 targeting CAR-T (chimeric antigen receptor-T) cells by knocking out PD-1 (programmed death 1) genes by virtue of CRISPR/Cas9 |
| CN106480027A (en) * | 2016-09-30 | 2017-03-08 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9 targeting knock out people PD 1 gene and its specificity gRNA |
| KR102622411B1 (en) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | AAV delivery of nucleobase editor |
| GB2605540B (en) | 2016-10-18 | 2022-12-21 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| CN106636212A (en) * | 2016-11-15 | 2017-05-10 | 西北农林科技大学 | Method for producing GDF9 (Growth/Differentiation Factor 9) gene edited goats by utilizing CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR associated protein 9) system |
| CN107058315B (en) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | Knockdown of human PD-1 siRNA, recombinant expression CAR-T vector and its construction method and application |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| CN106755097A (en) * | 2016-12-27 | 2017-05-31 | 安徽省农业科学院畜牧兽医研究所 | A kind of goat TLR4 gene knockout carriers and its construction method |
| CN106868008A (en) * | 2016-12-30 | 2017-06-20 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9 targeting knock outs people Lin28A genes and its specificity gRNA |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| CN107058358B (en) * | 2017-04-01 | 2020-06-09 | 中国科学院微生物研究所 | Construction of a double-spacer sequence-recognized cleavage CRISPR-Cas9 vector and its application in Verrucobacterium |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| KR20200018572A (en) * | 2017-06-20 | 2020-02-19 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Methods for knocking out target genes in T cells in vitro and cRCNAA used in the methods |
| SG10201705285SA (en) * | 2017-06-27 | 2019-01-30 | Agency Science Tech & Res | Antisense oligonucleotides |
| CN111511375A (en) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | Adeno-Associated Virus Vectors for Gene Therapy |
| CN107338305A (en) * | 2017-07-23 | 2017-11-10 | 嘉兴允英医学检验有限公司 | A kind of kit for the detection of the expressions of PD 1 |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| CN107475292B (en) * | 2017-08-02 | 2018-06-15 | 山东百福基因科技有限公司 | The preparation method of PD-1 gene defection type T lymphocyte preparations |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| JP7190096B2 (en) * | 2017-09-18 | 2022-12-15 | 博雅▲緝▼因（北京）生物科技有限公司 | Gene-edited T cells and uses thereof |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-1 |
| EP3697906A1 (en) | 2017-10-16 | 2020-08-26 | The Broad Institute, Inc. | Uses of adenosine base editors |
| CN108588071A (en) * | 2018-04-25 | 2018-09-28 | 和元生物技术（上海）股份有限公司 | The sgRNA of CRISPR-Cas9 targeting knock out people colon-cancer cell CNR1 genes and its specificity |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| WO2019237392A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Crispr/cas9 targeted knockout human sleb2 gene and specific grna thereof |
| CN108949693A (en) * | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | A kind of pair of T cell immune detection point access carries out the method and application of gene knockout |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN109971842A (en) * | 2019-02-15 | 2019-07-05 | 成都美杰赛尔生物科技有限公司 | A method of detection CRISPR-Cas9 undershooting-effect |
| JP7618576B2 (en) | 2019-03-19 | 2025-01-21 | ザ ブロード インスティテュート，インコーポレーテッド | Editing Methods and compositions for editing nucleotide sequences |
| RU2731293C1 (en) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Method of producing genetically modified lines of cells of natural killers with knockout pd-1 gene and high expression of proteins of family of tumour necrosis factor for immunotherapy of oncological diseases |
| CN112239769B (en) * | 2019-07-19 | 2023-11-07 | 上海邦耀生物科技有限公司 | An sgRNA that guides PD1 gene cleavage to achieve efficient integration of foreign sequences |
| EP4146804A1 (en) | 2020-05-08 | 2023-03-15 | The Broad Institute Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN112458116B (en) * | 2020-10-19 | 2023-04-14 | 广州重磅生物科技有限公司 | A method for constructing PD-1 knockout CD19CAR-T cells |
| CN113430202A (en) * | 2021-08-26 | 2021-09-24 | 山东兴瑞生物科技有限公司 | Human PD1 gene sgRNA with high knockout rate, plasmid containing sgRNA and T cell |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
-
2014
- 2014-03-04 CN CN201410077474.6A patent/CN103820454B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
Non-Patent Citations (2)
| Title |
|---|
| RNA-Guided Human Genome Engineering via Cas9;Prashant Mali等;《Science》;20130215;第339卷;823-825,附加材料 * |
| 刘思也和夏海滨.一种新的由CRISPR/Cas系统介导的基因组靶向修饰技术.《中国生物工程杂志》.2013,第33卷(第10期),114-123. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103820454A (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103820454B (en) | The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene | |
| CN103820441A (en) | Method for human CTLA4 gene specific knockout through CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat) and sgRNA(single guide RNA)for specially targeting CTLA4 gene | |
| Ungerleider et al. | The epstein barr virus circRNAome | |
| CN103923911B (en) | The method of CRISPR-Cas9 specific knockdown CCR5 gene and the sgRNA for selectively targeted CCR5 gene | |
| US12215366B2 (en) | Compositions and methods for epigenome editing | |
| Wang et al. | The CRISPR‐Cas13a gene‐editing system induces collateral cleavage of RNA in glioma cells | |
| AU2015299850B2 (en) | Genome editing using Campylobacter jejuni CRISPR/CAS system-derived RGEN | |
| US11104897B2 (en) | Compositions and methods for the treatment of nucleotide repeat expansion disorders | |
| CN105518135B (en) | CRISPR-Cas9 specific knockout method of porcine CMAH gene and sgRNA for specific targeting of CMAH gene | |
| CN112823011A (en) | Gene targets for T cell-based immunotherapy | |
| CN105886498A (en) | Method for specifically knocking out human PCSK9 gene by virtue of CRISPR-Cas9 and sgRNA for specifically targeting PCSK9 gene | |
| CN103911376A (en) | CRISPR-Cas9 targeted knockout hepatitis b virus cccDNA and specific sgRNA thereof | |
| CN105518138A (en) | Method knocking out pig GFRA1 genes with CRISPR-Cas9 specificity and sgRNA for specificity targeting GFRA1 genes | |
| CN107151677B (en) | Method for knocking out low transfection efficiency cell line based on CRISPR/Cas9 multiple genes | |
| CN103951733A (en) | Protein variant capable of inhibiting human tumor and application thereof | |
| US11072782B2 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
| Han et al. | Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs | |
| CN106987560A (en) | The construction method of the stable strain of the cell HB gene knockouts of RK 13 | |
| CA3163087A1 (en) | System and method for activating gene expression | |
| Bam et al. | Genome wide DNA methylation landscape reveals glioblastoma’s influence on epigenetic changes in tumor infiltrating CD4+ T cells | |
| CN109609551A (en) | A method of universal CAR-T cell is prepared using CRISPR/Cas9+AAV | |
| Chasov et al. | Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis | |
| Liu et al. | Tip110 binding to U6 small nuclear RNA and its participation in pre-mRNA splicing | |
| Godfrey et al. | Interaction sites of the Epstein–Barr virus Zta transcription factor with the host genome in epithelial cells | |
| Haddad et al. | Targeting the Kaposi’s sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160219 Address after: 201203 Shanghai city Chinese (Shanghai) free trade zone 351 GuoShouJing Road No. 2 building A679-05 room Applicant after: HUANG XINGXU Address before: 210061, No. twelve, Xuefu Road, Pukou hi tech Development Zone, Jiangsu, Nanjing Applicant before: Huang Xingxu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161017 Address after: 210061, No. twelve, Xuefu Road, Pukou hi tech Development Zone, Jiangsu, Nanjing Patentee after: Huang Xingxu Address before: 201203 Shanghai city Chinese (Shanghai) free trade zone 351 GuoShouJing Road No. 2 building A679-05 room Patentee before: HUANG XINGXU |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180620 Address after: 510660 room 227, A 227, Shi Huan Road, Tianhe District, Guangzhou, Guangdong. Patentee after: Esoteric Biotechnology (Guangzhou) Co., Ltd. Address before: 210061 twelve Xuefu Road, Pukou hi tech Development Zone, Nanjing, Jiangsu. Patentee before: Huang Xingxu |